A PHP Error was encountered

Severity: Warning

Message: Creating default object from empty value

Filename: libraries/Adodb.php

Line Number: 14

A PHP Error was encountered

Severity: 8192

Message: mysql_connect(): The mysql extension is deprecated and will be removed in the future: use mysqli or PDO instead

Filename: drivers/adodb-mysql.inc.php

Line Number: 364

The Third International Conference on Dengue and Dengue Haemorrhagic Fever “ Global Dengue : Challenges and Promises”




Scientific Program
Scientific Program

Tentative Scientific Program
3rd International Conference on Dengue and Dengue Haemorrhagic Fever 2013

(Update#12 Final-2: 17 October 2013)
 Download Scientific Program


20 October 2013
13.30-17.00 Registration and Poster Setup   
Contents 1: (Final)
21/10/2013
Room I
(Queen’s Park 1)
Room II
(Queen’s Park 2)
Room III
(Queen’s Park 3)
Room IV
(Queen s Park 4-5)
08.00 - 09.00 Registration
09.00 - 10.30 Opening Ceremony
Welcome Address:
(Ministry of Public Health)
Report by:
(Department of Disease Control)
Message from: Dr. Magaret Chan (Director General of WHO)

Opening remark:
Dr. Rajesh Bhapia (Representative,  Regional Director of WHO-SEARO)

Opening speech: (Ministry of Public Health)
10.30 - 11.00 Coffee break
Special Lecture
11.00 - 12.00 Scott B Halstead (USA): The basic science behind successful dengue vaccine
12.00 - 13.00 Luncheon Symposium 1 by Sanofi Pasteur:
The Growing Burden of Dengue: Southeast Asian and Global Perspectives
13.00-13.45  Poster presentation
Prof. Natth Bhamarapravati Memorial Lecture
13.30 - 14.00 Jean Lang (FRA): Thailand: Three decades at the forefront of dengue vaccine development
14.00 - 14.30 Sutee Yoksan (THA): Prof. Natth’s Initiation and achievement on dengue vaccine development

Symposium 1: Global Dengue Situation       

14.30-15.00 Duane Gubler (USA): Dengue-Global health problem and threat
 
15.00-15.20 A P Dash (WHO/SEARO) (cannot attend): Dengue in South East Asia

15.20-15.40 (WHO/WPRO) (cannot attend):
Dengue in Western Pasific

15.40-16.00 Kay Tomashek (USA): Emerging of dengue in USA
  
 

Symposium 2: Highlight from Fifty Years of Denge Experience and Research at Queen Sirikit National Institute of Child Health
14.30-15.00 Suchitra Nimmannitya (THA): Interweaving clinical experience with research works in dengue: Towards best achievement 
 
15.00-15.30 In-Kyu Yoon: Insights into host and viral factors in dengue severity
 
15.30-16.00 Anon Srikiatkhachorn: Clinical and immunologic studies at Queen Sirikit National Institute of Child Health

Symposium 3: Emerging Flavivirus and Epidemiology of DENV
Oral Presentation
14:30-14:45 (0215R01) Basu Dev Pandey (NPL)

14.45-15.00 (0025R01) Nikos Vasilakis (USA)
 
 
15.00-15.15 (0145R01) Robert Reiner (USA)

15.15-15.30 (0116R01) Bernard Cazelles (FRA)
 
15.30-15.45 (0246R01) Sowath Ly (KHM)

15.45-16.00 (0257R01) Alex Perkins (USA)       

Special Symposium by DVI:        Generating Evidence for Dicision Making regarding the Introduction of Dengue Vaccines

14.30-14.50 Pornthep Chanthavanich (THA):
Burden of dengue infection in children and adults of Bangpae district of Ratchaburi province

14.50-15.10 Jacqueline Lim (KOR) : Burden of dengue infection in children and adults of Santa cruz comuna of Medelin, Columbia
15.10-15.30 Jung Seok Lee (KOR): A multi-center study of the economic burden of dengue infection and household willingness to pay for dengue vaccines
15.30-15.50 Ira Longini (USA): Advances in mathemetical modeling to support dengue vaccine introduction and future work

16.00 - 16.30 Coffee break
Global Dengue Situation (Continued)

16.30-16.50 Harold Margolis (USA) (cannot attend): Dengue in Africa

16.50-17.20 Raman Velayudhan (WHO/GENEVA): Global strategy for dengue prevention and control
Symposium 4: Lesson Learned from Cohort Studies

16.30 - 16.50 Timothy Endy (USA): Lessons learned from prospective cohort studies on dengue transmission and disease severity
16.50 - 17.10 In-Kyu Yoon (USA): What we have learned from dengue cluster studies

 17.10 - 17.30 Chukiat Sirivichayakul (THA): Clinical manifestation of dengue; A cohort study
Symposium 5: Health Economic Communication and Community Empowerment
16.30 - 16.50 Ng Chiu Wan(MYS): Would economic burden of dengue infections in Malaysia do?

16.50 - 17.10 Veerle Vanlerberghe (BEL): Household uptake and use of intervention tools influencing the scale of effect of dengue vector control
Oral presentation
17.10-17.25  (0229R01) Raviwharmman Packierisamy (MYS)
Symposium 6:Epidemiology

 16.30 - 16.50 Karen Campbel: Using a dengue transmission model to inform prevention policy and decission making

16.50 - 17.10 Rome Buathong (THA): Seroprevalence and risk factors of dengue infection in Rayong province, Thailand, 2010

17.10- 17.30 Hasitha Tissera (LKA): Epidemiology of dengue in Sri Lanka: Evolution into a major public health and clinical entity
 19.00-21.30  Welcome Dinner
Contents 2: (Final)
22/10/2013
Room I
(Queen’s Park 1)
Room II
(Queen’s Park 2)
Room III
(Queen’s Park 3)
Room IV
(Queen s Park 4-5)
State of the Art Lecture 1:

08.30 - 09.15 Donald Robert (USA): The continuing need for public health insecticides in dengue control ?
Symposium 7: Laboratory Diagnosis

08.30 - 09.00 Ichiro Kurane (JAP): An overview on dengue diagnosis



09.00 - 09.30 Stefan Fernadez (USA):
Experience on diagnosis assays and value of rapid test for dengue diagnosis
Symposium 8: Activation and Evasion of Innate Immunology by Dengue Virus

08.30 - 08.50 Douglas Goldenboug (USA): Innate immunity and infectious diseases

08.50 - 09.10 Chia-Yi Yu (TWN): Activation and evasion of type I interferon response in dengue virus infection

09.10 - 09.30 Panisadee Avirutnan (THA): Complement response in dengue - a double edged sword
 Symposium 9: Vaccines I

Oral Presentation

08.30-08.45 (0114R01) Suh-Chin Wu (TWN)

08.45-09.00 (0142R01) Tamaki Okabayashi (JPN)




09.00-09.15 (0252R01) Martha Erika Navarro Sanchez (USA)         
Symposium 10: Innovative Vector Control and Approaches
09.15 - 09.40 Nicole Achee (USA): Spatial repellent products for dengue control

09.40 - 10.10 Vincent Corbel (FRA):
Molecular basis of insecticide resistance in Aedes aegypti and impact on space spray efficacy



10.10 - 10.30 Micheal J Bangs (USA):
Past, current and innovative approaches to a persistent challenge-dengue vector control
Symposium 11: Laboratory Diagnosis
Oral presentations
09.30-09.45 (0310R01) Elizabeth Hunsperger (PRI)


09.45-10.00
(0154R01) Anne-Claire Andries (KHM)


10.00-10.15 (0155R01) Kebaneilwe Lebani (AUS) 

10.15-10.30 (0198R01) Jorge L. Munoz-Jordan (PRI)      
Symposium 12: The Roles of Adaptive Immunity in Protection and Disease

09.30 - 09.50 Juthatip Mongkolsapaya (THA): The human antibody response to dengue virus

09.50 - 10.10 Alan Rothman (USA): Prospective studies of human T cell responses to dengue-what are the implications for vaccines and therapeutics?

10.10 - 10.30 Izabela Rodenhuis-Zybert (NLD) : New insights in antibody-dependent enhancement of dengue virus infection
Symposium 13: Vaccines II

Oral presentation
 09.30-09.45 (0186R01) Navin Khanna (IND)


09.45-10.00 (0347R01) Cholathip Pipattanaboon (THA)


10.00-10.15 (0363R01) Robert Beatty (USA)


10.15-10.30 (0218R01) Ada Alves (BRA)   
10.30 - 11.00 Coffee break
Symposium 14: Vector Biology and Behavior

11.00 - 11.20 Thomas Scott (USA):
The interplay between Aedes aegypti ecology and dengue epidermiology


11.20 - 11.40 John P Grieco (USA) (cannot attend): Aedes aegypti behavior: Potential impact on control interventions
11.40 - 12.00 Sylvie Manguin (FRA): Global invasion and biology of the Aedes mosquito and associated risk of dengue expansion
State of the Art Lecture 2:

11.00 - 11.30 Richard J Kuhn (USA): Dengue virus structure and dynamics

11.30 - 12.00 Ralf Bartenschlager (DEU): New insights into the dengue virus replication cycle

Symposium 15: Adaptive and Innate Immunity in Dengue
Oral presentations
11.00-11.15 (0130R01) Raphael Zellweger (USA)

11.15-11.30 (0157R01) Daniela Weiskopf (USA)

11.30-11.45 (0069R01) Wilawan Chan-in (THA)

11.45-12.00 (0275R01) Ruklanti de Alwis (USA)       
Symposium 16: Dengue Case Management: Points of Clinicians Concern

11.00-11.20 Siripen Kalayanarooj (THA): Dengue classifications and guidelines of clinical management: original WHO vs TDR 2009

11.20-11.40 LakKumar Fernando (LKA): Guidelines and Beyond: How to deal with some difficult situations

11.40-12.00 Tahira Cheema (PAK): Facing 2009 Lahore dengue epidemic
12.00 - 13.00 Luncheon Symposium by MP Medgroup and SD Standard Diagnostics, Inc.
Making diagnosis of Dengue in clinical practice
13.00-13.30 Poster Presentation
State of the Art Lecture 3:

13.30 - 14.00 Gravin Screaton (GBR): Overview on pathogenesis of dengue virus infection
Symposium 17: Biollogy of Dengue Virus and Dengue Virus-Host Interaction

13.30 - 14.00 Rushika Perera (USA): Alterations in cellular metabolism are key to dengue virus replication
Symposium 18: Integrated Vector Management (IVM)

13.30-14.00 Raman Velayudhan (WHO/GENEVA): Global strategy on integrated vector management
 
Symposium 19: Vascular Biology of Viral Hemorrhagic Fevers
14.00 - 14.25 Hans Schnittler: Dynamics of endothelial junctions

14.25 - 14.50 Christina Spiropouru (USA) (cannot attend): Disruption of the endothelial cell barrier by hantavirus infection

14.50 - 15.15 Anon Srikiatkhachorn (THA): Interaction between virus, immunity and endothelium in dengue
Oral presentations

14.00-14.15 (0028R01) Supranee Phanthanawiboon

14.15-14.30 (0219R01) Kenneth Hodge (THA)

14.30-14.45 (0242R01) Andrea Da Polan (BRA)

14.45-15.00 (0140R01) Andrew Davidson (GBR)

15.00-15.15 (0284R01) Pornapat Surasombatpattana (FRA)       

14.00-14.30 A P Dash (WHO/SEARO) (cannot attend): IVM strategy for dengue prevention and control in WHO South East Asian countries


14.30-15.00 Raman Velayudhan (WHO/GENEVA): WHOPES support judiceous use of insecticides according to IVM strategy

15.00-15.20 Christina Liew (SGP): Integrated vector management for dengue control in Singapore

15.20-15.40 Boonserm Aumaung (THA): Implementation of IVM for dengue prevention and control in Thailand   


Symposium 20: Hematologic Changes in Dengue Illness

14.00-14.30 Suchitra Nimmannitya (THA):
DHF- A unique viral hemorrhagic fever with pathophysiologic hallmarks of plasma leakage and hematologic derangement

14.30-15.00 Ampaiwan Chuansumrit (THA): Hematologic derangement in DHF and management on massive bleeding


15.00-15.30 Tanamsri Srichaikul (THA):
Bone marrow involvement and hemophagocytic syndrome in dengue
15.30-16.00 Coffee break
Symposium 21: Pathogenesis

16.00-16.20 Guey-Chuen Perng (TWN): Bone marrow stem/progenitor cells in dengue pathogenesis

16.20-16.50 Prida Malasit (THA) and Khin Saw Aye (MMR): Immuno-Histophathology studies of 13 autopsy cases of patients died of dengue hemorrhagic fever   


Oral presentations

16.50-17.05 (0240R01) Eugenia Ong (SGP):

17.05-17.20 (0391R01) Ashutson Biswas (IND):

17.20-17.35 (0129R01) Henry Stephens (GRB):   
Symposium 22: Vector and Vector Control

Oral presentations

16.00-16.15 (0123R01) Ahbi Rami Rattanam (MYS):

16.15-16.30 (0137R01) Emmanuel Elanga Ndille (BEN):

16.30-16.45 (0045R01) Nattapong Jupatanakul (THA):

16.45-17.00 (0112R01) George Dimopoulos (USA):

17.00-17.15 (0112R02) George Dimopoulos (USA):

17.15-17.30 (0110R01) Christine Joyce Hernandez (PHL):         
Symposium 23: Next Generation Dengue Vaccines
16.00-16.30 In-Kyu Yoon (USA): Walter Reed Army Institute of Research Dengue vaccine development efforts

16.30-17.00 Nopporn Sittisombut (THA): Generation and immunogenicity testings of insect cell-derived tetravalent chimeric dengue virus-like particles

17.00-17.30 Jannine R Danko (USA) (cannot attend): A Phase I clinical trial of tetravalent dengue DNA vaccine with Vaxfectin
Round Table Discussion on the Two Classifications: DF/DHF/DSS VS Mild/SevereDengue

16.00-19.00
Suchitra Nimmannitya (THA)

Hasitha Tissera (LKA)

Siripen Kalayanarooj (THA)
  

LakKumar Fernando (LKA)

Anon Srikiatkhachorn (THA)

Tran Tinh Hien (VNM   


 
Contents 3: (Final)
 23/10/2013
Room I
(Queen s Park 1)
Room II
(Queen s Park 2)
Room III
(Queen s Park 3) 
Room IV
(Queen’s Park 4-5)
State of the Art Lecture 4:
08.30 - 09.00 John Asskov (AUS): How does dengue evolution tell us about a sucessful dengue vaccine strategy?

09.00-09.30 Joachim Hombach (WHO/GENEVA) Global perspective on dengue vaccine development and introduction
 







09.00-10.30 Symposium 25:
Vector and Vector Control
Oral presentations
09.00-09.15 (0371R01) Peter Ryan (AUS)

09.15-09.30 (0193R01) Elizabeth Hunsperger (PRI)
8.30-9.30 Symposium 24: Clinical and Laboratory Diagnosis
Oral presentations
08.30-08.45 (0211R01) Kalamathy Murugananthan (LKA)

08.45-09.00 (0189R01) Elizabeth Hunsperger (PRI)

09.00-09.15 (0073R01) Pugpen Sirikutt (THA)


09.15-09.30 (0147R01) Kay Tomashek (PRI)
09.30-10.30 Symposium 26: Dengue Vaccine Under Clinical Trials I

09.30-09.50 Charung Muangchana (THA) Use of the first dengue vaccine in Thailand

09.50-10.10 Melanie Saville (FRA) Update on Sanofi Pasteur dengue vaccine development

10.10-10.30 Arunee Sabchareon (THA) Understanding the first dengue vaccine efficacy trial
09.30-10.30 Symposium 27: Tools for Vaccine Trial


09.30-09.50 Sujan Shresta (USA)
The Role of cellular and humoral immunity in dengue vaccination
Oral presentations
09.50-10.05 (0096R01) Takeshi Kurosu (JPN)

10.05-10.20 (0248R01) Kuan Rong Chan (SGP)
09.30-09.45 (0226R01) Gerhart Knerer (GBR)


09.45-10.00 (0271R01) Dawn M Wesson (USA)

10.00-10.15 (0181R01) Wasana Boonyuan (THA)

10.15-10.30 (0183R01) Sunaiyana Sathantriphop (THA)
09.30-10.35 Symposium 28: Dengue Virus Evolution and Epidemiology

09.30-09.50   Chonticha Klungthong (THA):  Evolution of dengue viruses in defined geographical space in Thailand
Oral presentations
09.50-10.05 (0039R01) Malayvanh Lao (LAO)

10.05-10.20 (0255R01) Eng Eong Ooi (SGP)


10.20-10.35 (0198R02) Jorge L. Munoz-Jordan (PRI)
    10.30 - 11.00 Coffee break  
11.00-12.00 Symposium 29: Dengue Vaccine Under Clinical Trials II

11.00-11.20   Anna Durbin (USA) NIAID LID/Butantan: Dengue vaccine ph 1, 2

11.20-11.40   Astrid Borkowski (USA) Inviragen DENVax ph 2 “Safety and immunogenicity of DENVax in diverse age groups and populations”

11.40-12.00   Dan Stinchcomb (USA) Dissecting the immune response to a chimeric dengue vaccine
11.00-12.00 Symposium 30: Clinical aspects and treatments
Oral presentations
11.00-11.15 (0148R01) Esther Ellis (PRI)

11.15-11.30 (0325R01) Victor Gan (SGP)

11.30-11.45 (0266R01) Ananda Wijewickrama (LKA)

11.45-12.00 (0068R01) Steven Moulton (USA) 
11.00-12.00 Symposium 31: Anti-Dengue Virus Agents

11.00-11.20 Wei-Kung Wang (USA) Stem region of dengue virus envelope protein as potential target of antiviral strategy

Oral presentations
11.20-11.35 (0009R02) Kazuyoshi Ikuta (JPN)

11.35-11.50 (0341R01) Andrew Sayce (GBR)

11.50-12.05 (0224R01) Nuno Santos (PRT)
11.00-12.00 Symposium 32: DENV Evolution and Vaccine
Oral presentations
11.00-11.15 (0210R01) Thanh Le Viet (VNM)

11.15-11.30 (0264R01) October Sessions (SGP)


11.30-11.45 (0164R01) Shuzhen Sim (SGP)

11.45-12.00 (0354R01) Luis Mier-y-Teran-Romero (USA) 
12.00 - 13.00 Luncheon Symposium by MP Medgroup and SD Standard Diagnostics, Inc.
13.00-14.00 Poster Presentation

14.00-14.40    FUNDING and RESEARCH OPPORTUNITIES in DENGUE
14.00-14.20   Cristina Cassetti (NIH) : NIAID Dengue Research Program and Funding Opportunities
14.20-14.40   Georges Thiry (DVI) : DVI’s perspective on dengue
14.40-15.45   PANEL DISCUSSION
1. Duane Gubler (USA)
2. Raman Velayudhan (WHO/GENEVA)
3. Pratap Singhasivanont (THA)
4. Prida Malasit (THA)

Dr. Supamit Chunsuttiwat (Moderator)

15.45-16.00   CLOSING SPEECH: Professor Emeritus Prasert Thongcharoen

Back to Top